QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors

DSpace/Manakin Repository

QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors

Citable link to this page

 

 
Title: QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors
Author: Ghatalia, P; Je, Y; Kaymakcalan, M D; Sonpavde, G; Choueiri, T K

Note: Order does not necessarily reflect citation order of authors.

Citation: Ghatalia, P, Y Je, M D Kaymakcalan, G Sonpavde, and T K Choueiri. 2015. “QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors.” British Journal of Cancer 112 (2): 296-305. doi:10.1038/bjc.2014.564. http://dx.doi.org/10.1038/bjc.2014.564.
Full Text & Related Files:
Abstract: Background: Multi-targeted vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs) are known to cause cardiac toxicity, but the relative risk (RR) of QTc interval prolongation and serious arrhythmias associated with them are not reported. Methods: We conducted a trial-level meta-analysis of randomised phase II and III trials comparing arms with and without a US Food and Drug Administration-approved VEGFR TKI (sunitinib, sorafenib, pazopanib, axitinib, vandetanib, cabozantinib, ponatinib and regorafenib). A total of 6548 patients from 18 trials were selected. Statistical analyses were conducted to calculate the summary incidence, RR and 95% CIs. Results: The RR for all-grade and high-grade QTc prolongation for the TKI vs no TKI arms was 8.66 (95% CI 4.92–15.2, P<0.001) and 2.69 (95% CI 1.33–5.44, P=0.006), respectively, with most of the events being asymptomatic QTc prolongation. Respectively, 4.4% and 0.83% of patients exposed to VEGFR TKI had all-grade and high-grade QTc prolongation. On subgroup analysis, only sunitinib and vandetanib were associated with a statistically significant risk of QTc prolongation, with higher doses of vandetanib associated with a greater risk. The rate of serious arrhythmias including torsades de pointes did not seem to be higher with high-grade QTc prolongation. The risk of QTc prolongation was independent of the duration of therapy. Conclusions: In the largest study to date, we show that VEGFR TKI can be associated with QTc prolongation. Although most cases were of low clinical significance, it is unclear whether the same applies to patients treated off clinical trials.
Published Version: doi:10.1038/bjc.2014.564
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453446/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:24983922
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters